File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical trial: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection

TitleClinical trial: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection
Authors
Issue Date2007
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2007, v. 26 n. 7, p. 1063-1067 How to Cite?
AbstractBackground: The efficacy of levofloxacin-based quadruple therapy in resistant Helicobacter pylori infection is not known. Aim: To test the efficacy of levofloxacin-based quadruple therapy and traditional quadruple therapy in resistant H. pylori infection. Methods: One hundred and two patients with resistant H. pylori infection were randomized to 1 week of either EBAL (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., amoxicillin 1 g b.d. and levofloxacin 500 mg b.d.) or EBMT (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., metronidazole 400 mg t.d.s. and tetracycline 500 mg q.d.s.). 13C-urea breath test was performed at week 12 to assess post-treatment H. pylori status. Results: In intention-to-treat analysis H. pylori eradication was achieved in 37 of 51 (73%) subjects in EBAL and 45 of 51 (88%) subjects in EBMT groups, respectively (P = 0.046). Per-protocol eradication rates of EBAL and EMBT groups were 78% and 94%, respectively (P = 0.030). The intention-to-treat eradication rate was statistically lower for EBAL than EMBT (56% vs. 90%, P = 0.013) among those who had failed more than one course of eradication therapy. Previous levofloxacin triple therapy did not affect the efficacy of either protocol significantly. Conclusions: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy for resistant H. pylori infection. © 2007 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/163106
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYee, YKen_US
dc.contributor.authorCheung, TKen_US
dc.contributor.authorChu, KMen_US
dc.contributor.authorChan, CKen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorChan, Pen_US
dc.contributor.authorBut, Den_US
dc.contributor.authorHung, Ien_US
dc.contributor.authorChan, AOOen_US
dc.contributor.authorYuen, MFen_US
dc.contributor.authorHsu, Aen_US
dc.contributor.authorWong, BCYen_US
dc.date.accessioned2012-09-05T05:27:40Z-
dc.date.available2012-09-05T05:27:40Z-
dc.date.issued2007en_US
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2007, v. 26 n. 7, p. 1063-1067en_US
dc.identifier.issn0269-2813en_US
dc.identifier.urihttp://hdl.handle.net/10722/163106-
dc.description.abstractBackground: The efficacy of levofloxacin-based quadruple therapy in resistant Helicobacter pylori infection is not known. Aim: To test the efficacy of levofloxacin-based quadruple therapy and traditional quadruple therapy in resistant H. pylori infection. Methods: One hundred and two patients with resistant H. pylori infection were randomized to 1 week of either EBAL (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., amoxicillin 1 g b.d. and levofloxacin 500 mg b.d.) or EBMT (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., metronidazole 400 mg t.d.s. and tetracycline 500 mg q.d.s.). 13C-urea breath test was performed at week 12 to assess post-treatment H. pylori status. Results: In intention-to-treat analysis H. pylori eradication was achieved in 37 of 51 (73%) subjects in EBAL and 45 of 51 (88%) subjects in EBMT groups, respectively (P = 0.046). Per-protocol eradication rates of EBAL and EMBT groups were 78% and 94%, respectively (P = 0.030). The intention-to-treat eradication rate was statistically lower for EBAL than EMBT (56% vs. 90%, P = 0.013) among those who had failed more than one course of eradication therapy. Previous levofloxacin triple therapy did not affect the efficacy of either protocol significantly. Conclusions: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy for resistant H. pylori infection. © 2007 The Authors.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_US
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_US
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAmoxicillin - Pharmacology - Therapeutic Useen_US
dc.subject.meshAnti-Bacterial Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshBreath Testsen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHelicobacter Infections - Drug Therapy - Metabolismen_US
dc.subject.meshHelicobacter Pylorien_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOfloxacin - Pharmacology - Therapeutic Useen_US
dc.subject.meshOmeprazole - Pharmacology - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleClinical trial: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infectionen_US
dc.typeArticleen_US
dc.identifier.emailChu, KM:chukm@hkucc.hku.hken_US
dc.identifier.emailFung, J:jfung@sicklehut.comen_US
dc.identifier.emailHung, I:ivanhung@hkucc.hku.hken_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityChu, KM=rp00435en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityHung, I=rp00508en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1111/j.1365-2036.2007.03452.xen_US
dc.identifier.pmid17877513-
dc.identifier.scopuseid_2-s2.0-34548666400en_US
dc.identifier.hkuros149101-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34548666400&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume26en_US
dc.identifier.issue7en_US
dc.identifier.spage1063en_US
dc.identifier.epage1067en_US
dc.identifier.isiWOS:000249482000010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridYee, YK=7004400469en_US
dc.identifier.scopusauthoridCheung, TK=7103334158en_US
dc.identifier.scopusauthoridChu, KM=7402453538en_US
dc.identifier.scopusauthoridChan, CK=7404813824en_US
dc.identifier.scopusauthoridFung, J=23091109300en_US
dc.identifier.scopusauthoridChan, P=7403497841en_US
dc.identifier.scopusauthoridBut, D=24343113400en_US
dc.identifier.scopusauthoridHung, I=7006103457en_US
dc.identifier.scopusauthoridChan, AOO=7403167965en_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridHsu, A=16204995400en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats